March 28, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Cautionary Email received from the stock exchanges regarding delay in intimation of Schedule of Investors Meet

Ref : 1) Email dated March 28, 2025 received from NSE

2) Email No. LIST/COMP/JP/1772/2024-25 dated March 28, 2025 received from BSE

This is to inform you that the Company has received cautionary emails from the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) regarding delay in intimation of Schedule of Investors meet held on June 10, 2024. Due to a delay in finalizing the meeting schedule and availability of participants, we were unable to intimate a schedule of the meet within the requisite timelines to the stock exchanges.

We are enclosing the aforesaid e-mails received from NSE and BSE.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.03.28 17:27:41 +05'30'

B. Adi Reddy
Company Secretary

Encl: as above.

(CIN : L24239TG1986PLC015190)
AUROBINDO PHARMA LIMITED
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Secretary Company

From: neaps@nse.co.in
Sent: 28 March 2025 16:00
To: Secretary Company
Subject: AUROPHARMA - Cautionary Email

Follow Up Flag: Flag for follow up
Flag Status: Flagged

CAUTION : * This email is originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and content is safe *****

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 06, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on June 10, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.
The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.
Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.

Secretary Company

From: Query lodr <query.lodr@bseindia.com>
Sent: 28 March 2025 16:22
To: Secretary Company
Subject: Cautionary Letter

CAUTION : * This email is originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and content is safe *****

LIST/COMP/JP/1772/2024-25 Date:
March 28, 2025

To,
Company Secretary /Compliance Officer
Aurobindo Pharma Ltd (524804)

Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 06, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on June 10, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team
BSE Limited
P J Towers, Dalal Street,
Mumbai - 400001, India
www.bseindia.com
Tel: 022 2272 8561 / 8475